Salvage Surgery Should be Considered for Selected Patients With NSCLC

Share this content:
Salvage surgery for locoregional recurrence of non-small cell lung cancer demonstrated promising outcome.
Salvage surgery for locoregional recurrence of non-small cell lung cancer demonstrated promising outcome.

Salvage surgery for locoregional recurrence of non-small cell lung cancer (NSCLC) or persistent tumor following high-dose chemoradiotherapy demonstrated acceptable morbidity, mortality, and promising outcome, a study published in the journal Lung Cancer has shown.1

There are limited curative intent treatment options for locoregional recurrence or persistent tumor after radical chemoradiotherapy for locally advanced NSCLC. In certain patients, salvage surgery may be feasible, but it is widely considered to be dangerous.

Therefore, researchers at VU University Medical Center in Amsterdam, the Netherlands, sought to evaluate clinical outcomes with salvage surgery at a single institution.

For the study, researchers retrospectively analyzed data from patients with NSCLC who underwent pulmonary resection after chemotherapy and radiation at a dose of 60 Gy or higher.

All patients were treated between January 2007 and August 2015. Of those, 87% received surgery for in-field locoregional recurrence while the rest had persistent tumor.

Results showed that the in-hospital morbidity rate was 40% and the 90-day mortality rate was 6.7% after a median follow-up of 12.1 months.

Researchers estimated that the median overall survival and event-free survival were 46 months and 43.6 months, respectively.

RELATED: TG4010 Vaccine Plus Chemo Appears Effective in Advanced NSCLC

The findings suggested that compared with other treatment options, salvage surgery can offer good survival.

“Salvage surgery should be considered as a treatment option for selected patients,” the authors concluded.

Reference

  1. Dickhoff C, Dahele M, Paul MA, et al. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer [published online ahead of print February 11, 2016]. Lung Cancer. doi: 10.1016/j.lungcan.2016.02.005.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs